Abstract Library

#3807 Key device attributes for Somatostatin Receptor Ligand (SRL) therapy in patients with neuroendocrine tumors (NETs)

Introduction: SRL injection effectiveness, safety and adherence are similar for independent vs healthcare setting administration, but patient preferences and satisfaction with devices vary. For other injectable hormones, device ease of use has been associated with more favourable outcomes. Elucidating preferred SRL device features should help HCPs decide which device best fits individual needs.

Conference:

Presenting Author: Martin W

Authors: Martin W, Kolarova T, Marks M, Follin C, de Herder W,

Keywords: NET, neuroendocrine tumor, somatostatin receptor ligands, SRL, device, preference,

#3190 Getting Results - Patient experiences and preferences for communicating scan results in Australia

Introduction: Scans are integral to neuroendocrine tumor (NET) management. There are no guidelines regarding timing of scans and results communication from a patient (pt.) perspective.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Gillespie J, Wakelin K, Cummins M, Golden K, Chan D,

Keywords: consumer, patient preferences, imaging, collaborative consumer research, communication, self-management, health service delivery,

#2989 Different Social Media Neuroendocrine Tumor Indexing Strategies Used by Physicians and Advocacy Groups

Introduction: The use of Twitter to disseminate medical content has increased over the last decade. Although Twitter activity by oncologists is clustered around international conferences, advocacy groups have different temporal social media patterns. Furthermore, given the non-standardized method of indexing tweets using Twitter hashtags, it can be difficult to follow the full breadth of a topic.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Meti N, Singh S,

Keywords: Neuroendocrine Tumor, Social Media, Twitter, Advocacy,

#2078 Self-Reported Side Effects in Neuroendocrine Tumor (NET) Patients Prescribed Somatostatin Analogues – The Role for Specialist Dietitians and Nurses

Introduction: In practice, many patients with NETs report a change in symptoms after starting somatostatin analogues (SSA’s). Many health professionals and NET patient advocates have noticed that some of the side effects experienced by patients are more common than patient information literature suggests. It is therefore important to ask what and how severe experiences are, and compare to literature, to help raise awareness amongst NET health professionals.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Whyand T, Davies P, Bouvier C,

Keywords: B12, SSA, Side effects, Fat soluble vitamins,

#728 NETworking-The First Three Years of the World NET Cancer Awareness Day Alliance

Introduction: Neuroendocrine tumors have an incidence of 3-5/100,000 per year, however, many patients are diagonosed late in their clinical course resulting in poor outcomes and early death. Raising awareness of the myriad presenting symptoms with resultant early diagnosis is a priority health care initiative for this disease. In 2010, the World NET Cancer Day Awareness (WNCAD) Alliance was formed with the primary mission to raise awareness of neuroendocrine tumors and promote November 10 as World NET Cancer Awareness Day

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Leyden J, Sissons M, Goldstein G,

Keywords: neuroendocrine, advocacy, internet, facebook, twitter, social media,